Diclomax and everolimus can be used as inhibitors of mammalian target of rapamycin (mTOR) to prolong progression‐free survival of patients with ccRCC by regulating hypoxia‐inducible factors associated metabolism and cellular proliferation through the PI3K‐Akt pathway [38, 39]. Here, PIK3CG is linked to nonpapillary renal cell carcinoma.